Journal
JOURNAL OF NEUROENDOCRINOLOGY
Volume 35, Issue 5, Pages -Publisher
WILEY
DOI: 10.1111/jne.13283
Keywords
chemotherapy; immunotherapy; neuroendocrine carcinoma; survival analysis
Categories
Ask authors/readers for more resources
Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers. EP NECs are typically treated with platinum-based regimens, and some clinicians have added a checkpoint inhibitor (CPI) to the treatment based on data from trials in patients with small cell carcinoma of the lung. However, a retrospective study did not find any additional benefit of adding CPI to the standard chemotherapy in EP NECs.
Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers characterized by a high Ki-67 index, rapid tumor growth and poor survival, and are subdivided into small and large cell carcinoma. For small cell carcinoma of the lung, a pulmonary NEC, the combination of cytotoxic chemotherapy (CTX) and a checkpoint inhibitor (CPI) is considered standard therapy and superior to CTX alone. EP NECs are typically treated with platinum-based regimens, some clinicians have adopted the addition of a CPI to CTX based on data from trials in patients with small cell carcinoma of the lung. In this retrospective study of EP NECs, we report 38 patients treated with standard first-line CTX and 19 patients treated with CTX plus CPI. We did not observe any additional benefit of adding CPI to CTX in this cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available